Immunopathogenesis of inflammatory myopathies

Annals of Neurology

Volumn 37, Issue 1 S, 1995, Pages 74-86

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BETA1 INTEGRIN; CARBAMAZEPINE; CD8 ANTIGEN; CHLORAMBUCIL; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LACTATE DEHYDROGENASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; METHYLPREDNISOLONE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DERMATOMYOSITIS; DRUG MEGADOSE; ELECTROMYOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE MEDIATED INJURY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE BIOPSY; MYOPATHY; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; SIDE EFFECT; WHOLE BODY RADIATION;

ATROPHY; AUTOIMMUNE DISEASES; CAPILLARIES; CELL ADHESION MOLECULES; COMPLEMENT; ENDOTHELIUM, VASCULAR; HUMAN; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR MIMICRY; MUSCLE FIBERS; MYOSITIS; NECROSIS; SUPERANTIGENS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS DISEASES;

EID: 0029071034     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410370709     Document Type: Article

References (81)

1. Polymyositis, dermatomyositis, and inclusion‐body myositis
2. Inflammatory myopathies: pathogenesis and treatment
3. The polymyositis and dermatomyositis syndrome
4. Cellular mechanisms in inflammatory myopathies
5. Pathology of the inflammatory myopathies
6. Polymyositis, inclusion body myositis and related disorders
7. Inflammatory myopathies Curr Opin Neurol
8. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and related disorders
9. Idiopathic inflammatory myopathies
10. The immunobiology of muscle
11. Is there dermatomyositis (DM) without myositis
12. Inclusion body myositis
13. Inclusion body myositis: new concepts
14. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light‐microscopic distinction from polymyositis
15. Amyloid filaments in inclusion body myositis
16. B‐amyloid protein immunoreactivity in muscle of patients with inclusionbody myositis
17. Light and electron microscopic localization of B‐amyloid protein in muscle biopsies of patients with inclusion‐body myositis
18. Immune mechanisms of myositis
19. Dermatomyositis (systemic angiopathy) of childhood
20. Dermatomyositis of childhood. Ultrastructural alterations of muscle and intramuscular blood vessels
21. Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies
22. The childhood type of dermatomyositis
23. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy
24. Microvascular deposition of complement membrane attack complex in dermatomyositis
25. Microvascular changes in early and advanced dermatomyositis: a quantitative study
26. High‐dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
27. Antibodies to endothelial cells in dermatomyositis: association with interstitial lung diseases
28. Anti‐endothelial cell antibodies (AECA) in dermatomyositis (DM)
29. Intercellular adhesion molecule‐I expression is upregulated in patients with dermatomyositis (DM)
30. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen‐specific cell‐mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies
31. Major histocompatibility complex class‐I antigen expression, immunolocalization of interferon subtypes and T‐cell‐mediated cytotoxicity in myopathies
32. Immunocytochemical and virological characteristics of HIV‐associated inflammatory myopathies: similarities with seronegative polymyositis
33. Polymyositis in patients infected with human T‐cell leukemia virus type I: the role of the virus in the cause of the disease
34. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy
35. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies
36. Monoclonal antibody analysis of mononuclear cells in myopathies. III. Immunoelectron microscopy aspects of cell‐mediated muscle fiber injury
37. Expression of activation markers on endomysial macrophages in patients with inflammatory myopathies
38. Molecular mechanisms of T‐cell mediated muscle fiber damage in polymyositis: role of perforin, granzyme‐A in cell death
39. Polymyositis mediated by T lymphocytes that express the gamma/delta receptor
40. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles
41. Viruses in the idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle
42. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies
43. Analysis of T cell receptor repertoire of muscle‐infiltrating T lymphocytes in polymyositis
44. Predominant TCR‐αβ variable and joining gene expression by muscle‐infiltrating lymphocytes in the idiopathic inflammatory myopathies
45. Infection of human muscle, nerve and motor neurons with polioviruses and other enteroviruses
46. Viral and retroviral myositis
47. Acute viral myositis
48. Detection of enterovirus specific RNA sequences in muscle biopsy specimens from patients with adult onset myositis
49. Inclusion body myositis: a chronic persistent mumps myositis
50. Inclusion body myositis: the mumps virus hypothesis
51. Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus
52. Morphological changes of an inflammatory myopathy in rhesus monkeys with simian acquired immunodeficiency syndrome (SAIDS)
53. Polymyositis in patients with AIDS
54. HTLV‐I and polymyositis in Jamaica
55. Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus gene
56. Neuromuscular diseases associated with human immunodeficiency virus infection
57. Retroviruses and inflammatory myopathies in humans and primates
58. Retroviral related neuromuscular disorders
59. Retroviral myopathies
60. HTLV‐I polymyositis in a patient also infected with the human immuno‐deficiency virus
61. Treatment of polymyositis and dermatomyositis with corticosteroids: a first therapeutic approach
62. Treatment of polymyositis and dermatomyositis
63. How to diagnose and treat the inflammatory myopathies
64. Current treatment of the inflammatory myopathies
65. Inflammatory myopathies
66. Interleukin‐1 (IL‐1) is toxic to human muscle
67. Pharmacologic concerns of corticosteroids in the treatment of patients with immune‐related neuromuscular diseases
68. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy
69. Cyclophosphamide in severe polymyositis
70. Chlorambucil: an effective corticosteroid‐sparing agent for patients with recalcitrant dermatomyositis
71. Cyclosporin in juvenile dermatomyositis
72. Cyclosporine A as first choice for dermatomyositis
73. A randomized double‐blind controlled trial of plasma exchange and leukapheresis in patients with polymyositis/dermatomyositis
74. Total body irradiation in the treatment of intractable polymyositis/dermatomyositis
75. Total body irradiation not effective in inclusion body myositis
76. Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients
77. Treatment of dermatomyositis with intravenous immunoglobulin
78. High‐dose intravenous human immunoglobulin in polymyositis resistant to treatment
79. A controlled trial of high‐dose intravenous immunoglobulin infusions as treatment for dermatomyositis
80. Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin